NGN Capital

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

PIN Pharma is a biopharmaceutical company dedicated to developing innovative immuno-modulatory therapies that connect the innate and adaptive immune systems. As a private, venture-backed research and development firm, PIN Pharma primarily focuses on oncology, specifically targeting breast and colon cancer. The company aims to create precision immune stimulants that address cancer-mediated immune suppression, thereby enhancing treatment options for physicians. Although its current emphasis is on oncology, the underlying technology has potential applications across a wide range of other disease areas.

Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Endosense is a medical technology company specializing in catheter ablation for the treatment of cardiac arrhythmias. The company has developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time, objective measure of contact force during procedures. Since receiving the CE mark in May 2009, the TactiCath has undergone extensive pre-clinical and clinical testing, establishing a strong foundation of evidence for the safety and efficacy of contact force sensing in catheter ablation. Through its innovative approach, Endosense aims to enhance the effectiveness and reproducibility of arrhythmia treatments.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

TME Pharma is a biotechnology company based in Berlin, Germany, focused on developing innovative therapeutics for cancer treatment. The company utilizes its proprietary Spiegelmer platform, which involves biostable aptamers and mirror image nucleic acids, to create a pipeline of clinical-stage product candidates. Its lead drug candidate, NOX-A12, is being investigated as a combination therapy for various cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. TME Pharma is also advancing NOX-E36, which has completed Phase IIa trials for diabetic nephropathy. The company has established partnerships, including a collaboration with Merck & Co. to explore the efficacy of NOX-A12 in combination with Keytruda in patients with metastatic solid tumors. Founded in 1997, TME Pharma continues to advance its mission of developing novel treatments for serious medical conditions.

Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases.

Valtech Cardio Ltd. is a medical device company based in Or Yehuda, Israel, specializing in the development and manufacturing of cardiovascular devices aimed at treating mitral regurgitation and facilitating tricuspid valve repair and replacement. The company focuses on minimally invasive transcatheter heart valve technologies, allowing patients to avoid open-heart surgery. Its key products include the Cardioband System, which performs mitral valve reconstruction via transfemoral direct annuloplasty, and the Cardiovalve system, a transfemoral transseptal replacement option for the mitral valve. Additionally, Valtech offers the Cardinal adjustable annuloplasty ring, which allows surgeons to optimize the ring size during surgery. The company's pipeline includes innovative products such as Cardioband Tricuspid, designed for mitral regurgitation, and V-Chordal, an adjustable implanted chord for repairing valve prolapse. Founded in 2006, Valtech Cardio operates as a subsidiary of Zeppelin Zox Ltd. since January 2017.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

SpineView develops and commercializes spine-related surgical and interventional products for spinal decompression and fusion applications. It offers flex Minimally Invasive Surgical (MIS) surgical discectomy system for facilitating discectomy and endplate preparation, including contralateral side and accelerating tissue removal in open and MIS discectomy procedures for interbody fusion. SpineView also provides MIS decompression system that is used to facilitate access and visualization in the surgical area of the cervical, thoracic, or lumbar spine and is accessorized with surgical instruments for interventional spinal procedures, such as discectomy, nucleotomy, and aminotomy. Moreover, it offers enSpire Interventional Discectomy System, tool to cut, grind, and aspirate disc tissue for lumbar discectomy procedures. SpineView offers its products through distributors. It began operation in 2005, with its headquarters in Fremont in California.

BeneChill, Inc. is a medical device company based in San Diego, California, specializing in non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Established in 2004, BeneChill has developed the RhinoChill System, which effectively reduces patient temperature to improve survival rates and recovery. The company operates primarily in the United States and Europe, focusing on innovative solutions for the healthcare sector.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Vivaldi Biosciences Inc., a clinical-stage biotechnology company, develops live attenuated influenza vaccines (LAIVs) for protection against seasonal influenza and preparedness against emerging pandemic influenza. It offers deltaFLU is an advanced, self-adjuvanting influenza vaccine, administered as a nasal spray. The company was founded in 2006 and is based in Fort Collins, Colorado.

ACT Biotech is a developer of innovative cancer therapies, concentrating on addressing the needs of underserved disease sectors. The company boasts a seasoned international leadership team with extensive expertise in clinical development and commercialization. With a robust portfolio of pre-clinical drug candidates, ACT Biotech has implemented a focused development strategy aimed at accelerating the delivery of effective therapeutic options for cancer patients. Its strengths and stability also create unique opportunities for corporate partnerships, which can further advance its promising and validated drug compounds.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

BeneChill, Inc. is a medical device company based in San Diego, California, specializing in non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Established in 2004, BeneChill has developed the RhinoChill System, which effectively reduces patient temperature to improve survival rates and recovery. The company operates primarily in the United States and Europe, focusing on innovative solutions for the healthcare sector.

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

Nitec is a specialty pharmaceutical company focused on the commercialization and development of medicines to treat chronic inflammation and pain-related diseases. It seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets. The Company is a spin-out of Merck KGaA and is headquartered in the Basel region of Switzerland. Since its formation in 2004, Nitec has developed and commercialized its lead product, Lodotraâ„¢. Nitecâ€:tm:s most advanced product candidate is Lodotraâ„¢, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. In January 2009, Lodotraâ„¢ was recommended for European regulatory approval for the treatment of rheumatoid arthritis (“RA”), particularly the associated and debilitating morning stiffness, following the successful completion of a phase III trial (CAPRA-1) in 2006. Germany was the Reference Member State and Lodotraâ„¢ is now also expected approvable by the regulatory agencies of 14 other countries under the Decentralized Procedure. In March Nitec announced a European partnership for Lodotraâ€:tm:s commercialization with MundiPharma. Merck KGaA, which holds the distribution rights to Lodotraâ„¢ in Germany and Austria, have recently launched the product in Germany. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotraâ„¢ for the treatment of the signs and symptoms of RA including morning stiffness. Lodotraâ„¢ is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR). Nitecâ€:tm:s second product candidate is TruNocâ„¢ (tarenflurbil), which is being developed as a treatment of neuropathic pain and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

EKOS Corporation pioneered the development and the clinical application of ultrasound accelerated thrombolysis, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System to provide faster, safer and more complete dissolution of thrombus.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

Small Bone Innovations (SBi) specializes in the development and manufacturing of medical devices aimed at small bones and joints, with a particular emphasis on trauma and arthroplasty. The company provides a range of implants designed for various anatomical areas, including the thumb, hand, wrist, elbow, foot, and ankle. Its product offerings include implants specifically designed to treat basal joint arthritis and those intended for replacing anatomic joint surfaces. SBi's innovations focus on preserving bone structure and minimizing disruption to collateral ligament origins and insertions, as well as soft skeletal implants, thereby enhancing surgical outcomes for patients with joint-related conditions.

Javelin Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products for the pain management market primarily in the United States and Europe. Its products focus on treating various pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain (orthopedic injury pain), procedural pain, and burn pain. The company's Dyloject (injectable diclofenac) received approval for marketing to treat post-operative pain in the United Kingdom and was licensed to Therabel Pharma N.V. for commercialization in the European Union and certain other countries outside the United States. Its products in the Phase 3 development stage in the U.S. include Dyloject (diclofenac sodium injectable), an injectable formulation of diclofenac and a prescription nonsteroidal anti-inflammatory drug that is used to treat post-operative pain due to its combination of effectiveness and tolerability; Ereska (intranasal ketamine), a proprietary nasal formulation; and Rylomine (intranasal morphine) for treatment of acute moderate-to-severe pain, including breakthrough pain. Javelin Pharmaceuticals has license agreements with Shimoda Biotech, Ltd. to develop and commercialize products related to a proprietary formulation of the injectable delivery of diclofenac; and West Pharmaceutical Services, Inc. to develop and commercialize intranasal morphine for the transmucosal delivery of morphine to humans and animals for the treatment of pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.

OptiScan Biomedical Corporation develops glucose monitoring systems for the intensive care unit (ICU)/CCU. It offers OptiScanner, an automated, bedside glucose monitoring system to assist healthcare providers manage the glucose level of critically ill patients. The company’s OptiScanner provides serial blood glucose measurements for a range of glucose concentrations. OptiScan Biomedical Corporation was founded in 1994 and is based in Hayward, California.

Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

EKOS Corporation pioneered the development and the clinical application of ultrasound accelerated thrombolysis, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions around the world use the EKOS EkoSonic Endovascular System to provide faster, safer and more complete dissolution of thrombus.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company that develops and commercializes innovative medicines for rare neuromuscular and pulmonary diseases, addressing high unmet medical needs. The company focuses on a product portfolio for Duchenne muscular dystrophy (DMD), including late-stage candidates such as Puldysa (idebenone) and vamorolone, which aim to treat patients regardless of their specific mutations, disease stage, or age. Additionally, Santhera's clinical pipeline includes lonodelestat (POL6014) for cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy for congenital muscular dystrophies. The company also out-licenses the rights to its approved product Raxone (idebenone) for Leber's hereditary optic neuropathy outside North America and has collaborated with Cold Spring Harbor Laboratory to explore lonodelestat as a potential treatment for COVID-19-related acute respiratory distress syndrome. Headquartered in Pratteln, Switzerland, Santhera primarily generates its revenue from the European Union.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.